Childhood Cancer Data Initiative (CCDI): Whole Genome Landscapes of Patient Derived Osteosarcoma Xenograft Models

Osteosarcoma is the most common primary bone malignancy in children and young adults and has few treatment options. As a result, there has been little improvement in survival outcomes over the past few decades. The need for models to test novel therapies is especially great for this disease because it is both rare and unresponsive to most therapies. To address this need, an NCI-funded consortium has characterized and utilized a panel of patient-derived xenograft models of osteosarcoma for drug testing. The exomes, transcriptomes, and copy number landscapes of these models have been described previously. This study adds whole-genome sequencing (WGS) and reverse-phase protein array profiling data, which can be correlated with drug testing results. In addition, four new osteosarcoma models are described for use by the research community.